Momotaro-Gene Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Out of Business
Momotaro-Gene General Information
Description
Developer of cancer therapeutic drug intended to research and commercialize cancer suppressor genes for curative purposes. The company's drug offers reduced expression in Immortalized cell (REIC) gene drug is administered in the human body, which then assists the body to fight cancer cells, enabling doctors to assist cancer patients effectively.
Contact Information
Website
www.mt-gene.comCorporate Office
- Okayama Medical Innovation Center Incubation Facility Number 25
- 2-5-1 Shikata-cho, Kita-ku, Okayama Prefecture
- Okayama, 700-8558
- Japan
Corporate Office
- Okayama Medical Innovation Center Incubation Facility Number 25
- 2-5-1 Shikata-cho, Kita-ku, Okayama Prefecture
- Okayama, 700-8558
- Japan
Momotaro-Gene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 03-Aug-2026 | Completed | Out of Business | |||
| 5. Secondary Transaction - Private | 01-Mar-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 14-Dec-2020 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 15-Mar-2019 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 26-Dec-2017 | $10.4M | $11.6M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 22-Jul-2016 | $1.21M | $1.21M | Completed | Pre-Clinical Trials |
Momotaro-Gene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred C | ||||||||
| Preferred B | ||||||||
| Preferred A | 4,672 | $2399.52 | $2399.52 | 1x | $2399.52 | 36.09% |
Momotaro-Gene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Momotaro-Gene Patents
Momotaro-Gene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4190362-A1 | Agent including reic/dkk-3 gene for treating egfr gene mutation positive lung cancer | Inactive | 31-Jul-2020 | ||
| EP-4190362-A4 | Agent including reic/dkk-3 gene for treating egfr gene mutation positive lung cancer | Inactive | 31-Jul-2020 | ||
| WO-2022025178-A1 | Agent including reic/dkk-3 gene for treating egfr gene mutation positive lung cancer | Inactive | 31-Jul-2020 | ||
| US-20230310653-A1 | Therapeutic agent for egfr gene mutation-positive lung cancer comprising reic/dkk-3 gene | Pending | 31-Jul-2020 | ||
| EP-4008349-A1 | Method for treating liver cancer with combined use of reic/dkk-3 gene and anti-tumor agent | Inactive | 31-Jul-2019 | A61K38/1709 |
Momotaro-Gene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Momotaro-Gene FAQs
-
When was Momotaro-Gene founded?
Momotaro-Gene was founded in 2007.
-
Where is Momotaro-Gene headquartered?
Momotaro-Gene is headquartered in Okayama, Japan.
-
What is the size of Momotaro-Gene?
Momotaro-Gene has 7 total employees.
-
What industry is Momotaro-Gene in?
Momotaro-Gene’s primary industry is Drug Discovery.
-
Is Momotaro-Gene a private or public company?
Momotaro-Gene is a Private company.
-
What is Momotaro-Gene’s current revenue?
The current revenue for Momotaro-Gene is .
-
How much funding has Momotaro-Gene raised over time?
Momotaro-Gene has raised $17.2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
